Doug Hampton

Music Therapy Market to Expand at 9.4% CAGR till 2031| Growth Market Reports

by

PUNE, India, May 22, 2023 /PRNewswire/ — According to a recent market study published by Growth Market Reports, titled, “Music Therapy Market Segments – by Type (Receptive and Active), Application (Traumatic, Chronic Pain, Substance Abuse Disorder, and Neurodevelopment Disorder), End-user (School, Hospital, Rehabilitation Center, and Prison & Jail), and Region: Size, Share, Trends and Opportunity Analysis, … Read more

Grünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

by

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis. The U.S. Food and Drug Administration’s … Read more

Pharmaceutical Filtration Market to be Worth $21.96 Billion by 2030: Grand View Research, Inc.

by

SAN FRANCISCO, May 22, 2023 /PRNewswire/ — The global pharmaceutical filtration market size is estimated to reach USD 21.96 billion by 2030, registering a CAGR of 8.03% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.03% from 2023 to … Read more

IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors

by

IDE397 (MAT2A) and AMG 193 (PRMT5) combination being evaluated in an Amgen-sponsored Phase 1/2 clinical trial in MTAP-deletion solid tumors Potential first-in-class synthetic lethality combination targets mechanistically complementary nodes of the MTAP methylation pathway – MAT2A and PRMT5 Compelling preclinical anti-tumor efficacy presented at AACR 2023 with durable CRs for IDE397 / AMG 193 combination, … Read more

SprintRay Launches Ceramic-Infused 3D Printing Resins for High Performance Dentures

by

Features FDA 510(k) cleared High Impact Denture Base resin, the first ceramic-infused 3D printing material for denture bases, and certified biocompatible High Impact Denture Teeth resin Leverages proprietary, future-forward NanoFusion™ technology that suspends the optimal amount of ceramic, with minimal mixing, for superb denture strength and fracture resistance Introduces new, simplified treatment planning with SprintRay … Read more

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

by

DUNDALK, Ireland, May 22, 2023 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facility of the Year Award (FOYA) in the Operations category. WuXi Biologics was recognized for using innovative … Read more

Music to slow cognitive decline

by

Researchers from the University of Geneva have shown that playing the piano and actively listening to music slows down cognitive decline. Specifically, an increase in gray matter has been observed in certain regions of the brain, involved in memory in particular. Explanations. Music would be able to slow down age-related cognitive decline. This is what … Read more

HHC cannabis derivative: sellers anticipate ban

by

(AFP) – “We have already sold our stocks and returned batches to suppliers”. Marc, a seller in Paris of products based on hexahydrocannabinol (HHC), has prepared for the probable banning of this molecule derived from cannabis. The Minister of Health, François Braun, judged on May 15 “abnormal” that HHC-based products are on free sale and … Read more

EVOLUTION RESEARCH GROUP, LLC REORGANIZES ITS CLINICAL SITE SERVICES BY THERAPEUTIC AREA PORTFOLIOS (TAPs) AND ANNOUNCES LEADERSHIP TEAM APPOINTMENTS

by

NEW PROVIDENCE, N.J., May 22, 2023 /PRNewswire/ — Evolution Research Group (ERG), a privately held, independent clinical development services organization focused on the execution of complex clinical programs has announced a reorganization of its clinical site operations to align under Therapeutic Area Portfolios (TAPs). The TAPs will be led by four industry veterans, Dr. Harold … Read more